Research areas

  • Mechanisms of resistance to monoclonal antibody therapy in B-cell malignancies
  • Targeted gene editing and whole-genome knockout screens using CRISPR/Cas9 technology for prediction of novel targeted therapies
  • Repurposing of approved drugs for personalized therapy in solid and hematological cancers

Main objectives

Content of research

Management

Michal Šmída
Michal Šmída
Research Group Leader Junior
Personal Profile